News monitor
GLP-1 Medicare and market news.
A daily monitored feed of GLP-1 stories related to Medicare, CMS, FDA safety updates, coverage policy, pricing, access, prior authorization, and supply.
What is this GLP-1 news feed?
This is a monitored feed of GLP-1 Medicare, CMS, FDA, pricing, access, coverage, supply, and market stories from public sources. Each item links back to the original source.
Who is the GLP-1 news feed for?
It is for beneficiaries, caregivers, counselors, clinicians, journalists, and researchers tracking GLP-1 coverage changes, Medicare policy, drug approvals, safety notices, and access signals.
How do I subscribe to GLP-1 Medicare news?
Use the RSS button above or add /news/rss.xml to an RSS reader. News items are informational and should be verified against original CMS, FDA, plan, pharmacy, or source documents.
FDA What's New: Drugs · 6/15/2026
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA What's New: Drugs · 6/15/2026
FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs
FDA is concerned about telehealth companies promoting compounded drugs, including glucagon-like peptide-1 receptor agonists (GLP-1s) and other drugs, with false or misleading claims.
Drugs.com FDA Alerts · 6/10/2026
FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
Audience: Consumer, Patient, Health Care Provider, Pharmacy, Gastroenterology, Nephrology, Endocrinology June 10, 2026 -- The FDA has approved changes to the Drugs Facts Label of the over-the-counter (OTC) weight loss drug, alli (orlistat) 60 mg...
FDA MedWatch · 6/10/2026
FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
The FDA has approved changes to the Drugs Facts Label of the over-the-counter (OTC) weight loss drug, alli (orlistat) 60 mg capsules, to warn of risks of acute kidney injury, which is a rare side effect of the medication. The labeling now advises consumers to ask a health care provider before using
FDA What's New: Drugs · 6/10/2026
FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
The Food and Drug Administration (FDA) has approved changes to the Drugs Facts Label of the over-the-counter (OTC) weight loss drug, alli (orlistat) 60 mg capsules, to warn of risks of acute kidney injury, which is a rare side effect of the medication.
FDA What's New: Drugs · 5/27/2026
Information by Drug Class
FDA provides consumers and industry with safety, regulatory and availability information for various drugs by drug class. From A to Z. Topics include: acetaminophen, estrogen, insulin, opioids, statins, and weight-loss drugs.
KFF Health News Prescription Drugs · 5/18/2026
Trump Bought Stock in Drugmaker as His Government Boosted Its Obesity Drugs
CMS Newsroom
Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries
KFF Medicare · 5/11/2026
What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge
KFF Health News Medicare · 5/6/2026
A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
FDA Press Releases · 4/30/2026
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
FDA is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.
KFF Medicare · 4/23/2026
CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage
Drugs.com New Drug Approvals · 4/1/2026
FDA Approves Foundayo (orforglipron), the Only GLP-1 Pill for Weight Loss That Can be Taken Any Time of Day Without Food or Water Restrictions
INDIANAPOLIS, April 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical...
Drugs.com New Drug Approvals · 3/19/2026
FDA Approves Novo Nordisk’s New Wegovy HD Injection, Delivering the Highest Weight Loss to Date for a Wegovy Injection
PLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy, Wegovy HD (semaglutide) injection 7.2 mg, which demonstrated substantial weight loss in...
Drugs.com FDA Alerts · 1/13/2026
FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications
Audience: Health Care Professional, Consumer January 13, 2026 FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications This information is an update to the FDA Drug Safety...
Drugs.com FDA Alerts · 12/5/2025
Novo Nordisk Warns Consumers About Counterfeit Ozempic (semaglutide) Injection 1 mg in the US
Audience: Consumer PLAINSBORO, NJ, December 5, 2025 - FDA recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg distributed illegally outside of Novo Nordisk’s authorized supply chain. The US Food and Drug...